Liu ZhaoXi, Zhang ZiQing, Yu GuoFang, Mo MingJiang, Xie ChuanYu, Xu DangHan, Lin JieTao, Zhang YuChen, Deng Li, Luo YiChang, Huang YingFeng, Shao Cui
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China.
Therap Adv Gastroenterol. 2025 Jan 22;18:17562848241311114. doi: 10.1177/17562848241311114. eCollection 2025.
Alkaline phosphatase (ALP) is a potential cancer biomarker. However, its prognostic value in patients with colorectal liver metastasis remains unclear.
This study aimed to investigate the association between ALP levels and mortality risk in patients with colorectal liver metastases (CRLM), providing insights for enhancing prognostic assessments.
Retrospective cohort study.
This study included 195 patients with CRLM from a single centre in China. ALP level was the primary exposure variable, with demographic, clinical and pathological factors serving as covariates. Multivariate Cox regression analyses were used to evaluate the impact of ALP on mortality over a 4-year follow-up period. Covariates included the number of liver metastases, T stage, N stage, chemotherapy, tumour location, primary surgery, topical treatment, apolipoprotein A1, targeted therapy, tumour type, CA-199 levels, metastatic surgery, sex, Karnofsky Performance Status and age.
Of 195 enrolled patients, 134 (68.72%) were male, and 61 (31.28%) were female, with ages ranging from January 2008 to December 2019. A total of 147 patients (76.96%) were diagnosed with left hemicolon cancer and 44 (23.04%) with right hemicolon cancer. After adjusting for the covariates, elevated ALP levels were significantly associated with an increased risk of mortality (hazard ratio = 1.24, 95% confidence interval: 1.08-1.43, = 0.0029). Sensitivity analyses confirmed the robustness of these findings, reinforcing the association across different analytical approaches.
ALP level is a valuable prognostic indicator in patients with CRLM. Integrating ALP measurement into clinical practice may enhance risk stratification and patient management. Future research should explore the role of ALP in broader populations and explore its implications for treatment strategies.
碱性磷酸酶(ALP)是一种潜在的癌症生物标志物。然而,其在结直肠癌肝转移患者中的预后价值仍不明确。
本研究旨在探讨碱性磷酸酶水平与结直肠癌肝转移(CRLM)患者死亡风险之间的关联,为加强预后评估提供见解。
回顾性队列研究。
本研究纳入了来自中国单一中心的195例CRLM患者。碱性磷酸酶水平是主要暴露变量,人口统计学、临床和病理因素作为协变量。采用多变量Cox回归分析评估碱性磷酸酶在4年随访期内对死亡率的影响。协变量包括肝转移灶数量、T分期、N分期、化疗、肿瘤位置、初次手术、局部治疗、载脂蛋白A1、靶向治疗、肿瘤类型、CA-199水平、转移灶手术、性别、卡诺夫斯基功能状态和年龄。
在195例纳入研究的患者中,134例(68.72%)为男性,61例(31.28%)为女性,年龄范围为2008年1月至2019年12月。共有147例患者(76.96%)被诊断为左半结肠癌,44例(23.04%)为右半结肠癌。在对协变量进行调整后,碱性磷酸酶水平升高与死亡风险增加显著相关(风险比=1.24,95%置信区间:1.08-1.43,P=0.0029)。敏感性分析证实了这些发现的稳健性,强化了不同分析方法之间的关联。
碱性磷酸酶水平是CRLM患者的一个有价值的预后指标。将碱性磷酸酶检测纳入临床实践可能会加强风险分层和患者管理。未来的研究应探讨碱性磷酸酶在更广泛人群中的作用,并探索其对治疗策略的影响。